Teva loses patent case for glaucoma treatment

Allergan has met its burden to prove Teva’s proposed generic Lumigan infringes upon its patent.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) infringed upon Allergan Inc.’s (NYSE AGN) patents for its glaucoma treatment Lumigan, ruled a judge in the US federal District Court for the District of Delaware.

Allergan sued Teva’s Barr Laboratories unit in 2009 over the two patents and a non-jury trial was held in January and February, according to court papers.

“Allergan has met its burden” to prove Teva’s proposed generic Lumigan infringes, and the defendants “have not proven by clear and convincing evidence” that the patents are invalid,’’ wrote US District Judge Sue L. Robinson.

The newest of the patents expires in 2014, according to U.S. Food and Drug Administration records.

Teva fell 2.7% on Nasdaq on Friday to $38.49, giving a market cap of $34.3 billion and fell 3.2% to NIS 142.00 in morning trading on the TASE today.

Published by Globes [online], Israel business news - www.globes-online.com - on September 11, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters âìåáñ Israel Business Conference 2018